We reviewed the medical records of patients aged 18 years or older who received thrombolytic treatment between 2015 and 2022, diagnosed with acute minor stroke or high-risk TIA (negative diffusion-weighted imaging on follow-up). Exclusion criteria were NIHSS>5, cardioembolic stroke, stroke mimics, intracranial bleeding after thrombolysis and absence of complete follow-up (90 days).
Antiplatelet therapy was initiated 24 hours after thrombolysis based on the physician's judgment and maintained for 21 to 180 days. Patients were divided in two groups: single and dual antiplatelet therapy. We assessed the modified Rankin scale -mRS-, symptomatic intracranial hemorrhage (SICH) and mortality at 90 days.
Fifty-three patients were enrolled, 68% were men aged 64 ±16,5 years. There were no differences in baseline characteristics. Seventy-five percent had ischemic stroke. Forty-nine percent were in the single antiplatelet group, and fifty-one percent were in the dual antiplatelet group.
There was no difference in the 90-day mRS. No patients experienced SICH or mortality during the follow-up. One patient in the single antiplatelet group had a stroke recurrence.